These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18274085)

  • 1. New tools for assessing breast cancer recurrence.
    Dinh P; Cardoso F; Sotiriou C; Piccart-Gebhart MJ
    Cancer Treat Res; 2008; 141():99-118. PubMed ID: 18274085
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tumor markers of breast cancer].
    Sławicki S; Mroczko B; Szmitkowski M
    Postepy Hig Med Dosw (Online); 2004 Jul; 58():292-300. PubMed ID: 15280799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification of ductal carcinoma in situ: striving for clinical relevance in the era of breast conserving therapy.
    Schnitt SJ; Connolly JL
    Hum Pathol; 1997 Aug; 28(8):877-80. PubMed ID: 9269821
    [No Abstract]   [Full Text] [Related]  

  • 4. Oncotype DX test on unequivocally HER2-positive cases: potential for harm.
    Bhargava R; Dabbs DJ
    J Clin Oncol; 2012 Feb; 30(5):570-1. PubMed ID: 22231038
    [No Abstract]   [Full Text] [Related]  

  • 5. The possibility of accurate prediction of recurrence rates after mastectomy.
    Bulbrook RD; Wang DY; Millis RR; Hayward JL
    Eur J Cancer (1965); 1980; Suppl 1():35-6. PubMed ID: 7032942
    [No Abstract]   [Full Text] [Related]  

  • 6. A Comparison of the Hot Spot and the Average Cancer Cell Counting Methods and the Optimal Cutoff Point of the Ki-67 Index for Luminal Type Breast Cancer.
    Arima N; Nishimura R; Osako T; Nishiyama Y; Fujisue M; Okumura Y; Nakano M; Tashima R; Toyozumi Y
    Oncology; 2016; 90(1):43-50. PubMed ID: 26613521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum human epidermal growth factor receptor 2 levels as a real-time marker for tumor burden in breast cancer patients.
    Kim HA; Lee JK; Kim EK; Seol H; Noh WC
    J Surg Oncol; 2014 Apr; 109(5):421-5. PubMed ID: 24783266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast.
    Provenzano E; Hopper JL; Giles GG; Marr G; Venter DJ; Armes JE
    Eur J Cancer; 2003 Mar; 39(5):622-30. PubMed ID: 12628841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic indicators of prognosis in breast cancer.
    Robert NJ
    Hosp Pract (Off Ed); 1990 Oct; 25(10):93-8, 101-2. PubMed ID: 2120258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
    Foulkes WD
    J Natl Cancer Inst; 2004 Jul; 96(13):1040-1; author reply 1041. PubMed ID: 15240792
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection of the first recurrence during intensive follow-up of breast cancer patients.
    Imoto S; Jitsuiki Y
    Jpn J Clin Oncol; 1998 Oct; 28(10):597-600. PubMed ID: 9839498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating and tissue markers in the longitudinal management of breast cancer patients.
    Schwartz MK
    Adv Exp Med Biol; 1994; 353():47-53. PubMed ID: 7985541
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic Tests for Estrogen Receptor-Positive Breast Cancer: Need for Global Consideration and Further Evolution.
    Kim JY; Kim SI; Paik S
    JAMA Oncol; 2016 Feb; 2(2):180-2. PubMed ID: 26633601
    [No Abstract]   [Full Text] [Related]  

  • 14. Analytical validation of CanAssist-Breast: an immunohistochemistry based prognostic test for hormone receptor positive breast cancer patients.
    Attuluri AK; Serkad CPV; Gunda A; Ramkumar C; Basavaraj C; Buturovic L; Madhav L; Naidu N; Krishnamurthy N; Prathima R; Kanaldekar S; Bakre MM
    BMC Cancer; 2019 Mar; 19(1):249. PubMed ID: 30894144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reply to L. Cabel et al.
    Fehrenbacher L; Capra A; Habel L
    J Clin Oncol; 2015 Jan; 33(3):292-3. PubMed ID: 25512452
    [No Abstract]   [Full Text] [Related]  

  • 16. Tests for detecting recurrent disease in the follow-up of patients with breast cancer.
    Mansi JL; Earl HM; Powles TJ; Coombes RC
    Breast Cancer Res Treat; 1988 Jul; 11(3):249-54. PubMed ID: 3167230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Locoregional recurrence].
    Winzer KJ
    Kongressbd Dtsch Ges Chir Kongr; 2002; 119():52-7. PubMed ID: 12704868
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognosis of t1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas.
    Cabel L; Péron J; Cottu PH; Rodrigues MJ
    J Clin Oncol; 2015 Jan; 33(3):291. PubMed ID: 25512462
    [No Abstract]   [Full Text] [Related]  

  • 19. Osteopontin C mRNA expression is associated with a poor clinical outcome in human breast cancer.
    Patani N; Jiang W; Mokbel K
    Int J Cancer; 2008 Jun; 122(11):2646. PubMed ID: 18302153
    [No Abstract]   [Full Text] [Related]  

  • 20. Summary report of the Standards, Options and Recommendations for the use of serum tumour markers in breast cancer: 2000.
    Basuyau JP; Blanc-Vincent MP; Bidart JM; Daver A; Deneux L; Eche N; Gory-Delabaere G; Pichon MF; Riedinger JM;
    Br J Cancer; 2003 Aug; 89 Suppl 1(Suppl 1):S32-4. PubMed ID: 12915901
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.